Antimicrobial Use Guidelines (AMUG) version 21 - UW Health

17. Maertens J, Glasmacher A, Herbrecht R, Thiebaut A, Cordonnier C, Segal BH, Killar J,Taylor A, Kartsonis N, Patterson TF. Multicenter, noncomparative study of caspofunginin combination with other antifungals as salvage therapy in adults with invasiveaspergillosis. Cancer 2006;Published online 11/13/2006.18. Wingard JR. Lipid formulations of amphotericins: are you a lumper or a splitter? ClinInfect Dis 2002;35(7):891-5.19. Leenders AC. Reiss P. Portegies P. Clezy K. Hop WC. Hoy J. Borleffs JC. Allworth T.Kauffmann RH. Jones P. Kroon FP. Verbrugh HA. de Marie S. Liposomal amphotericin B(AmBisome) compared with amphotericin B both followed by oral fluconazole in thetreatment of AIDS-associated cryptococcal meningitis. AIDS 1997;11(12):1463-71.20. Bennett JE. Dismukes WE. Duma RJ. Medoff G. Sande MA. Gallis H. Leonard J. FieldsBT. Bradshaw M. Haywood H. McGee ZA. Cate TR. Cobbs CG. Warner JF. Alling DW. Acomparison of amphotericin B alone and combined with flucytosine in the treatment ofcryptococcal meningitis. N Engl J Med 1979;301(3):126-31.21. Sobel J. Practice guidelines for the treatment of fungal infections. Clin Infect Dis2000;30(4):652-70.22. Saag MS. Powderly WG. Cloud GA. Robinson P. Grieco MH. Sharkey PK. ThompsonSE. Sugar AM. Tuazon CU. Fisher JF. et al. Comparison of amphotericin B withfluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. TheNIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med1992;326(2):83-9.23. van Duin D, Cleare W, Zaragoza O, Casadevall A, Nosanchuk JD. Effects ofvoriconazole on Cryptococcus neoformans. Antimicrob Agents Chemother 2004;48:2014-20.24. Powderly WG. Saag MS. Cloud GA. Robinson P. Meyer RD. Jacobson JM. Graybill JR.Sugar AM. McAuliffe VJ. Follansbee SE. et al. A controlled trial of fluconazole oramphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquiredimmunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses StudyGroup. N Engl J Med 1992;326(12):793-8.25. Pfaller MA. Messer SA. Hollis RJ. Jones RN. SENTRY Participants Group. Antifungalactivities of posaconazole, ravuconazole, and voriconazole compared to those ofitraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. andother filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.Antimicrob Ag Chemother 2002;46(4):1032-7.26. Wheat J, Sarosi G, McKinsey D, Hamill R, Bradsher R, Johnson P, Loyd J, Kauffman C,Practice guidelines for the management of patients with histoplasmosis. InfectiousDiseases Society of America. Clin Infect Dis 2000;30:688-95.27. Torres HA, Hachem RY, Chemaly, Kontoyuannus DP, Raad II. Posaconazole: a broadspectrum triazole antifungal. Lancet Infec Dis 2005;5:775-8528. Greenberg RN, Mullane K, vanBurik JA, Raad I, Abzug MJ, Anstead G, Herbrecht R,Langston A, Marr KA, Schiller G, Schuster M, Wingard JR, Gonzalez CE, Revankar SG,Corcoran G, Kryscio RJ, Hare R. Posaconazole as salvage therapy for zygomycosis.Antimicrob Agents Chemother 2006;50:126-133.29. Gotzsche, PC. Johansen, HK. Routine versus selective antifungal administration forcontrol of fungal infections in patients with cancer. Cochrane Gynaecological CancerGroup. Cochr Database System Rev 2003; 1.30. Walsh TJ. Finberg RW. Arndt C. Hiemenz J. Schwartz C. Bodensteiner D. Pappas P.Seibel N. Greenberg RN. Dummer S. Schuster M. Holcenberg JS. Liposomalamphotericin B for empirical therapy in patients with persistent fever and neutropenia.National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med1999;340(10):764-71.31. Wingard JR. White MH. Anaissie E. Raffalli J. Goodman J. Arrieta A. LAmph/AMPHOTERICIN B LIPID COMPLEX Collaborative Study Group. A randomized,double-blind comparative trial evaluating the safety of liposomal amphotericin B versusamphotericin B lipid complex in the empirical treatment of febrile neutropenia. L